Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A post hoc Evaluation of Data from the HAWK and HARRIER Trials.
Saved in:
| Title: | Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A post hoc Evaluation of Data from the HAWK and HARRIER Trials. |
|---|---|
| Authors: | Singer, Michael1 (AUTHOR), Khanani, Arshad M.2 (AUTHOR), Wolf, Armin3 (AUTHOR), Flores, Rita4,5 (AUTHOR), Chhablani, Jay6 (AUTHOR), B, Guruprasad7 (AUTHOR), Clemens, Andreas8,9 (AUTHOR), Gedif, Kinfemichael7 (AUTHOR), Liu, Xiaoxi7 (AUTHOR), Mulyukov, Zufar8 (AUTHOR), Querques, Giuseppe10,11 (AUTHOR) |
| Source: | Ophthalmologica. 2022, Vol. 245 Issue 4, p315-322. 8p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
